See more : Sydinvest Megatrends A DKK (SYIMEGADKK.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Mangalam Drugs & Organics Limited (MANGALAM.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mangalam Drugs & Organics Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- GBLT Corp. (GBLTF) Income Statement Analysis – Financial Results
- Strike Energy Limited (STX.AX) Income Statement Analysis – Financial Results
- Verisante Technology Inc. (VRSEF) Income Statement Analysis – Financial Results
- Amazon.com, Inc. (0R1O.IL) Income Statement Analysis – Financial Results
- Arctic Fox Minerals Corp. (FOXY.CN) Income Statement Analysis – Financial Results
Mangalam Drugs & Organics Limited (MANGALAM.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mangalamdrugs.com
About Mangalam Drugs & Organics Limited
Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. It offers a range of API products, which include Acyclovir, Amodiaquine, Artemether, Artesunate, Atazanavir Sulfate, Bisoprolol Fumarate, Chloroquine Phosphate, Dihydroartemisinin, and Dolutegravir Sodium; Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin Anhydrous and Monohydrate; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; and Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. The company also offers intermediates comprising 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and Tenofovir Alafenamide Base and Disoproxil Base. In addition, it offers specialty chemicals, such as Menthol; 2,3-Dihydrophthalazine-1, 4-dione; and 4-cynoethyl-2-methyl phenol. Further, the company's products under development include Tafenoquine Succinate, Bictegravir Na, Favipiravir, and Molnupiravir; and Elvitegravir, Cobicistat, Daclatasvir dihydrochloride, Ledipasvir, and Velpatasvir. The company was incorporated in 1972 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.69B | 3.66B | 4.47B | 3.80B | 2.82B | 2.24B | 2.79B | 3.04B | 2.95B | 2.21B | 1.23B | 1.25B | 1.53B | 1.27B | 1.12B | 1.02B | 949.99M |
| Cost of Revenue | 2.95B | 2.96B | 3.49B | 2.82B | 2.19B | 1.76B | 1.92B | 2.19B | 2.30B | 1.80B | 960.34M | 1.14B | 1.23B | 1.02B | 972.27M | 894.26M | 851.70M |
| Gross Profit | 737.76M | 701.50M | 987.43M | 976.69M | 630.92M | 475.36M | 866.60M | 854.56M | 653.46M | 408.36M | 264.82M | 111.89M | 305.07M | 258.35M | 150.65M | 129.77M | 98.30M |
| Gross Profit Ratio | 20.02% | 19.17% | 22.07% | 25.72% | 22.36% | 21.23% | 31.04% | 28.08% | 22.15% | 18.51% | 21.62% | 8.93% | 19.92% | 20.28% | 13.42% | 12.67% | 10.35% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.16M | 32.04M | 13.59M | 56.00K | 7.92M | 8.23M | 9.34M | 10.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 95.14M | 92.50M | 77.70M | 62.43M | 72.46M | 64.19M | 72.40M | 65.04M | 70.24M | 32.51M | 23.52M | 28.32M | 48.33M | 35.68M | 28.57M | 25.53M | 20.72M |
| Selling & Marketing | 69.33M | 61.91M | 72.94M | 71.83M | 48.66M | 34.57M | 42.46M | 60.66M | 59.12M | 54.67M | 34.59M | 31.60M | 21.72M | 22.34M | 15.37M | 13.39M | 13.66M |
| SG&A | 164.47M | 154.41M | 150.64M | 134.26M | 121.12M | 98.76M | 114.86M | 125.70M | 70.24M | 87.18M | 58.11M | 59.92M | 70.05M | 58.02M | 43.94M | 38.92M | 34.37M |
| Other Expenses | 542.23M | 835.00K | 344.00K | 333.00K | 2.78M | 1.49M | 1.75M | 2.36M | 382.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 706.70M | 555.63M | 599.78M | 532.22M | 475.62M | 448.91M | 463.75M | 437.66M | 319.29M | 245.57M | 206.46M | 179.65M | 192.05M | 159.72M | 68.99M | 61.05M | 52.88M |
| Cost & Expenses | 3.66B | 3.51B | 4.09B | 3.35B | 2.67B | 2.21B | 2.39B | 2.63B | 2.62B | 2.04B | 1.17B | 1.32B | 1.42B | 1.18B | 1.04B | 955.31M | 904.58M |
| Interest Income | 958.00K | 2.97M | 1.00K | 6.22M | 8.00M | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | -10.25M | -5.94M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 139.17M | 89.21M | 72.02M | 63.21M | 64.96M | 66.16M | 86.05M | 66.63M | 63.36M | 69.95M | 75.46M | 89.97M | 95.71M | 68.59M | 57.22M | 51.32M | 32.82M |
| Depreciation & Amortization | 146.51M | 109.89M | 102.49M | 91.75M | 82.18M | 70.89M | 65.68M | 50.07M | 44.13M | 41.54M | 40.11M | 39.40M | 37.36M | 32.73M | 29.71M | 25.84M | 23.00M |
| EBITDA | 139.86M | 109.89M | 491.44M | 579.77M | 248.75M | 99.98M | 476.96M | 462.24M | 377.21M | 171.58M | 98.46M | -28.37M | 150.39M | 131.36M | 111.38M | 96.98M | 70.83M |
| EBITDA Ratio | 3.79% | 6.05% | 10.08% | 14.49% | 7.41% | 3.70% | 15.72% | 14.32% | 11.84% | 7.78% | 6.24% | -2.26% | 9.82% | 10.31% | 10.13% | 9.47% | 7.46% |
| Operating Income | 27.46M | 150.97M | 355.66M | 443.24M | 163.22M | 27.86M | 407.29M | 421.43M | 333.16M | 130.04M | 36.40M | -67.77M | 113.02M | 98.63M | 84.08M | 71.14M | 47.83M |
| Operating Income Ratio | 0.74% | 4.13% | 7.95% | 11.67% | 5.78% | 1.24% | 14.59% | 13.85% | 11.29% | 5.90% | 2.97% | -5.41% | 7.38% | 7.74% | 7.49% | 6.95% | 5.04% |
| Total Other Income/Expenses | -138.19M | -128.83M | -78.33M | -48.05M | -92.77M | -83.82M | -109.37M | -105.09M | -94.01M | -69.95M | -97.42M | -100.22M | -101.64M | -68.59M | -59.64M | -53.74M | -35.24M |
| Income Before Tax | -110.73M | 22.14M | 277.33M | 395.19M | 62.52M | -57.37M | 293.47M | 311.81M | 240.16M | 60.09M | -39.06M | -167.99M | 11.38M | 30.04M | 22.03M | 14.98M | 10.18M |
| Income Before Tax Ratio | -3.00% | 0.60% | 6.20% | 10.41% | 2.22% | -2.56% | 10.51% | 10.25% | 8.14% | 2.72% | -3.19% | -13.41% | 0.74% | 2.36% | 1.96% | 1.46% | 1.07% |
| Income Tax Expense | -20.02M | 9.44M | 80.76M | 115.48M | -20.00M | 22.94M | 94.58M | 89.06M | 79.83M | -1.32M | -8.67M | -50.00M | 5.04M | 9.16M | 3.80M | 2.30M | 1.60M |
| Net Income | -90.72M | 12.70M | 196.58M | 279.71M | 82.53M | -80.31M | 198.90M | 222.75M | 160.33M | 61.41M | -30.39M | -117.99M | 6.34M | 20.88M | 18.23M | 12.68M | 8.58M |
| Net Income Ratio | -2.46% | 0.35% | 4.39% | 7.36% | 2.92% | -3.59% | 7.13% | 7.32% | 5.43% | 2.78% | -2.48% | -9.42% | 0.41% | 1.64% | 1.62% | 1.24% | 0.90% |
| EPS | -5.73 | 0.80 | 12.42 | 17.67 | 5.21 | -5.07 | 12.57 | 14.07 | 11.15 | 4.66 | -2.31 | -8.95 | 0.48 | 1.58 | 1.38 | 0.96 | 0.65 |
| EPS Diluted | -5.73 | 0.80 | 12.42 | 17.67 | 5.21 | -5.07 | 12.57 | 14.07 | 10.13 | 4.66 | -2.31 | -8.95 | 0.48 | 1.58 | 1.38 | 0.96 | 0.65 |
| Weighted Avg Shares Out | 15.83M | 15.83M | 15.83M | 15.83M | 15.83M | 15.83M | 15.83M | 15.83M | 14.38M | 13.18M | 13.18M | 13.18M | 13.18M | 13.18M | 13.18M | 13.18M | 13.18M |
| Weighted Avg Shares Out (Dil) | 15.83M | 15.83M | 15.83M | 15.83M | 15.83M | 15.83M | 15.83M | 15.83M | 15.83M | 13.18M | 13.18M | 13.18M | 13.18M | 13.18M | 13.18M | 13.18M | 13.18M |
Source: https://incomestatements.info
Category: Stock Reports